maendeleo mujarabfter HIV enters certain white blood cells, called CD4 T cells, the cells commit suicide and trigger inflammation. This alerts other disease-fighting cells that rush to the scene, but they fall into a trap that causes them to kill themselves, too, which often leads to a vicious cycle of abortive infection, cell death, inflammation and recruitment of new cells that are destined to the same fate.
yaan kila siku znakuja l;akin atujui zinaishiaga wapi!!!!mwenye uelewa afunguke
[COLOR=#444444 said:After HIV enters certain white blood cells, called CD4 T cells, the cells commit suicide and trigger inflammation. This alerts other disease-fighting cells that rush to the scene, but they fall into a trap that causes them to kill themselves, too, which often leads to a vicious cycle of abortive infection, cell death, inflammation and recruitment of new cells that are destined to the same fate.
[/COLOR]
The process links the two signature events in HIV/AIDS, Greene said: the depletion of CD4 T cells and chronic inflammation. Monkeys, however, have evolved so their bodies do not mount an attack on simian immunodeficiency virus but, instead, control the inflammatory response to the virus. The virus even different versions of it still is present, but it doesn't set off the chain of events that cause inflammation. Greene's lab believes there are existing drugs that could chemically reproduce this evolutionary jump in humans, blocking the inflammation pathway connected to T cell death. One drug, in particular, has caught Greene's eye.
The targeted drug inhibits an enzyme known as caspase 1. That enzyme is involved in pyroptosis, the process where the membrane of a T cell leaks its contents, triggering high-level inflammation. By viewing biopsied lymph nodes of HIV patients at San Francisco General Hospital, Greene's 17-person lab confirmed that the process occurs in untreated HIV-infected subjects. Greene's lab then went looking for already developed caspase 1 inhibitors. It found one in particular that had failed clinical trials for chronic seizures but was safe and well tolerated. Gladstone now is in negotiations with the company that controls the drug.